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ABSTRACT
Type 2 diabetes is a chronic condition primarily self-managed by 
the individual. Mastery is a protective factor linked to better control 
of chronic conditions, effective self-management and improved 
medication adherence. Mastery appears increasingly important as 
treatment regimens and self-management demands become more 
complex and burdensome. Diabetes distress negatively impacts 
self-management, glycaemic control and treatment adherence. 
Understanding the relationship between diabetes distress and mas-
tery may provide opportunities to improve condition management 
and adherence . This relationship may be impacted by other factors 
affecting the individual's perceived sense of control over their con-
dition. This study examined the role of diabetes empowerment and 
depression in the relationship between diabetes distress and mas-
tery. Data were drawn from a randomised controlled trial of 131 
adults with type 2 diabetes transitioning to injection therapy. 
Participants completed measures of diabetes distress , mastery , 
depression and empowerment . Diabetes distress and depression 
were negatively associated with mastery, whilst diabetes empow-
erment was positively associated . A significant interaction effect 
(b = .024, t(112) = 3.79, p = <.005) confirmed the relationship 
between diabetes distress and mastery was moderated by depres-
sion. Findings highlight the additive deleterious effects of depres-
sion. Interventions to improve mastery among those living with 
type 2 diabetes should address diabetes distress and depression 
to optimise outcomes.
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Introduction
Type 2 diabetes (T2D) is a condition predominantly managed by the individual 
(McSharry et al., 2019). To be effective self-managers, those with T2D need to 
make decisions regarding medication, diet, exercise and blood glucose monitoring 
(Skinner et al., 2006). Effective self-management is necessary to ensure appropriate 
glycaemic control and reduce diabetes-related complications (Wilkinson et al., 2014). 
Treatment advice for T2D advocates lifestyle and dietary change as the first option to 
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achieve optimal glycaemic control; if control remains poor, oral medications are 
prescribed, progressing to injection therapy i.e. GLP-1 receptor agonists or insulin 
(Edelman & Pettus, 2014). However, approximately 1 in 3 express a reluctance to 
commence prescribed injection therapy, with up to 80% discontinuing or interrupting 
treatment relatively quickly following initiation (Perez-Nieves et al., 2017, 2016; 
Peyrot et al., 2012). Poor engagement with injectable therapies corresponds to con-
cerns around the impact of injectables on daily living, treatment complexity and the 
restrictive nature of injectable regimens (Allen et al., 2017). Individuals who feel they 
have little control over their T2D and are unable to reach treatment targets report less 
motivation to manage their condition often irrespective of other factors (Gonzalez 
et al., 2016).
Mastery is recognised as a health-related protective factor, with higher levels of 
mastery related to better control of chronic conditions (Roepke & Grant, 2011). 
Mastery is considered: the extent to which individuals perceive aspects of their lives to 
be under their control, their ability to manage these aspects in light of the challenges they 
bring and their capacity to take appropriate action to affect associated positive outcomes 
(Forgeard & Benson, 2019). Mastery is positively associated with improved health 
behaviours (O’Kearney et al., 2020). Individuals with higher levels of mastery are more 
likely to engage in better self-management, adherence to diabetes treatment plans and 
medication management (Daniel et al., 2001; Roepke & Grant, 2011). Therefore, under-
standing more about factors which contribute to an individual’s level of mastery, 
particularly when changes in medication regimen are demanded, may provide insight 
to improve engagement and adherence.
Whilst mastery may serve as a positive protective factor, other factors can adversely 
affect adherence and self-management (Assari & Lankarani, 2017; Gonzalez et al., 2016; 
Linetzky et al., 2017; Spain et al., 2016). Diabetes distress refers to the negative psycho-
logical effects of living with diabetes and is linked to poor self-management, poor 
glycaemic control and difficulties with adherence (Dennick et al., 2017; Linetzky et al., 
2017). Due to these link interventions targeting diabetes distress are receiving further 
attention as potential methods to improve outcomes for those living with diabetes 
(Hessler et al., 2020). Understanding the impact of diabetes distress on mastery among 
a population of those transitioning to injection therapy would provide insights for 
clinicians tasked with improving condition management and adherence among this 
group. This cannot be explored as a simple direct relationship; other factors should be 
considered. Depression is often presented as a comorbid condition in those living with 
T2D and is associated with poorer clinical outcomes, initiation of injectable therapies, 
medication adherence and motivation which impacts negatively on effective self- 
management behaviours (Lee, 2015; Nefs et al., 2013). Feelings of disempowerment 
associated with their diabetes are a further indicator of medication resistance and poorer 
outcomes (Linetzky et al., 2017).
Mastery is important for effective self-management and may be more potent as 
management of T2D becomes more complex. Thus, understanding more about mastery 
and factors that impact this among a T2D population transitioning to injectable therapies 
has potential to provide additional insights for clinicians and educators aiming to 
improve engagement with and adherence to injectable therapies. With this in mind the 
aim of this study is to examine the role of depression and diabetes empowerment as 
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moderators in the relationship between diabetes distress and mastery among a sample of 
those with T2D as they transition from oral medications to injectables. Based on the 
existing literature it was hypothesised that the relationship between diabetes distress and 
mastery would be moderated by depression and empowerment, with the interaction 
between patients’ distress levels at high levels of depression and low levels of diabetes 
empowerment reflecting greater reductions in mastery.
Materials and methods
This study used baseline data drawn from a randomised controlled trial (RCT) of 
a structured diabetes education intervention. Individuals were eligible to participate in 
the trial if they: had a diagnosis of T2D for one year or more; were aged over 25 years; had 
HbA1c level of 58–100 mmol/mol; and required transfer from oral hypoglycaemic 
treatment to injectable therapies as judged by the diabetes healthcare team. Exclusion 
criteria meant individuals: newly diagnosed with T2D; with HbA1c >100 mmol/mol; 
undergoing retinal photocoagulation therapy or renal dialysis treatment; in receipt of 
psychiatric support or clinical psychology input; within 3 months of a major event 
including MI, stroke or major surgery; within 3 months of diagnosis or treatment of 
a major coexisting medical condition, were not eligible for inclusion. All participants 
attended a secondary care diabetes service in Northern Ireland delivered by a consultant- 
led, multidisciplinary team comprising Diabetologists/Endocrinologists, Diabetes 
Specialist Nurses and Diabetes Specialist Dietitians. Eligible participants were identified 
by a member of this multi-disciplinary care team. Participants provided informed 
consent to participate. Ethical approval was granted by the Office of Research Ethics 
Committee in Northern Ireland, with governance from the Trust Research Governance 
Committee prior to the commencement of participant recruitment [15/NI/0091].
Participants
The sample comprised 131 participants diagnosed with T2D transitioning to injectable 
therapies for effective management of the condition. Mean diabetes duration was 
10.4 years (HbA1c M = 70.3 mmol/mol; SD = 12.31). Age ranged from 39 to 85 years 
(M = 62.3; SD = 8.8); 59.5% of participants were male.
Measures
Once eligible participants were identified and informed consent obtained, participants 
were asked to complete and return two questionnaires, one providing demographic 
information (see supplementary online materials for sample characteristics) and 
the second consisting of the following measures taken at baseline.
Diabetes distress
The Problem Areas in Diabetes Scale (PAID: Polonsky et al., 1995), comprising 20 
statements, is a reliable and valid measure of emotional distress specific to diabetes 
(Huang et al., 2010; Polonsky et al., 1995; Welch et al., 2003). Scored on a 5-point 
Likert scale (0 = not a problem; 4 = serious problem), scores range from 0 to 100, 
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with higher scores indicative of higher levels of emotional distress (Welch et al., 
1997).
Mastery
The Pearlin Mastery Scale (PMS:Pearlin & Schooler, 1978) is a reliable and valid, 
unidimensional measure used to assess the extent to which individuals feel they have 
control over stressful events in their lives (Pearlin et al., 1981; Pearlin & Schooler, 1978; 
Turner & Noh, 1988). The scale comprises seven items, with higher scores indicative of 
greater levels of mastery (Brady, 2003).
Depression
The Hospital Anxiety and Depression Scale (HADS: Zigmond & Snaith, 1983) is 
a reliable and valid measure for assessing anxiety and depression among hospital out- 
patients, including adults with diabetes (Bjelland et al., 2002; Lloyd et al., 2000). 
Comprising 14 items (7 items in each subscale) assessing the severity of anxiety and 
depression; scored on a 4-point Likert scale. Subscale scores range from 0 to 21, with 
scores of 0–7 considered normal, and scores ≥11 moderate to severe (Collins et al., 
2009).
Diabetes empowerment
The Diabetes Empowerment Scale – Short Form (DES-SF: Anderson et al., 2003) is a brief, 
reliable and valid measure assessing overall diabetes-related self-efficacy (Anderson et al. 
2003). The scale comprises eight items, scored on a 5-item scale (1 = strongly disagree; 
5 = strongly agree). Higher scores are indicative of greater empowerment.
In the current sample, the reliability of the scores on each scale was found to be 
acceptable with Cronbach’s alpha ranging from 0.95 (PAID) to 0.84 (HADSD).
Analysis
The aim of this study is to examine the role of diabetes empowerment (M1) and 
depression (M2) in the relationship between diabetes-specific distress (X) and mastery 
(Y). To test this, a moderated model (Figure 1) was specified and tested in SPSS using 
PROCESS (Hayes, 2013). PROCESS ‘uses logistic regression-based path analytical frame-
work for estimating direct and indirect effects in simple and multiple moderation models’ 
(Hayes, 2018, p. 1). In PROCESS, R2 is used to assess model fit (Hayes, 2013).
Results
Model summary
The model was found to be a good fit for the data, with included variables accounting for 
approximately 54% of the variance in mastery among the group: R2 = .539, F(5, 
112) = 26.22, p = <.0001.
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Main effects
Regression coefficients (Table 1) for the model indicate diabetes distress (b = −.249, t 
(5,112) = −3.71, p = <.005), diabetes empowerment (b = .280, t(5,112) = 3.02, p = <.005) 
and depression (b = −.980, t(5,112) = −5.73, p = <.005) are all statistically significant 
predictors of mastery. The main effects show diabetes distress and depression are 
negatively associated with mastery. Diabetes empowerment is positively associated with 
mastery.
Interactions
A significant interaction between diabetes-specific distress and depression was found 
(b = .024, t(112) = 3.79, p = <.005), indicating the magnitude of the effect of diabetes 
distress on mastery depends on level of depression. No significant interaction effect was 
found for diabetes distress and empowerment. PROCESS provides additional outputs on 
the change in the variance explained in the outcome due to the addition of the interac-
tion. Results show no significant change in variance explained by mastery due to the 














Figure 1. Conceptual and statistical diagram of proposed moderation model.
Table 1. Model summary: path coefficients for estimated model using PROCESS.
Coefficient 
(std error) T P LLCI;ULCI
Constant 30.213 
(1.53)
19.71 p = .000 27.18;33.25
Diabetes specific distress (X) −.249 
(.07)
−3.71 p < .001 −.38;-.12
Diabetes empowerment (M1) .280 
(.09)
3.02 p < .001 .10;.46
Diabetes specific distress x Diabetes empowerment (X M1) .003 
(.004)
.68 p = .500 −.00;.01
Depression (M2) −.980 
(.17)
−5.73 p < .001 −1.32;-.64
Diabetes specific distress x Depression (XM2) .024 
(.01)
3.79 p < .001 .01;.04
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p = .50, ∆R2 = .001. There was a significant increase in variance explained due to the 
interaction of diabetes distress x depression: F(1,112) = 14.40, p = <.005, ∆R2 = .06.
Figure 2 illustrates the interaction between diabetes distress and depression more 
clearly: increasing levels of distress, at increased levels of depression, are indicative of 
lower levels of mastery, regardless of the level of diabetes empowerment.
Discussion
This study used data drawn from an RCT of adults living with T2D transitioning to 
injectable therapies to examine the role of diabetes empowerment and depression in the 
relationship between diabetes distress and mastery. It was hypothesised that the relation-
ship between diabetes distress and mastery would be moderated by depression and 
empowerment, in essence individuals experiencing diabetes distress, high levels of 
depression and low levels of empowerment would report the lowest levels of mastery. 
Using Hayes’ (2013) PROCESS moderation model, this study evidenced that diabetes 
distress, diabetes empowerment and depression significantly impact levels of mastery. 
Direct relationships indicated diabetes distress and depression were negatively associated 
with mastery, in essence in this cohort, as diabetes distress or depression increase, 
mastery decreases. These relationships are consistent with the existing literature that 
highlights the negative impact of distress and depression (Dennick et al., 2016; Lee, 2015; 
Linetzky et al., 2017). Diabetes empowerment was positively associated with mastery, i.e. 
as diabetes empowerment increases in this grouping, so too does mastery.
Figure 2. Relationship between diabetes distress and mastery at different levels of the moderators.
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The significant interaction between diabetes distress and depression highlights how 
the negative impact of diabetes distress on mastery is heightened by increasing levels of 
depression with this interaction creating greater reduction in mastery. Additionally, there 
was no significant interaction for diabetes empowerment and distress. Further findings 
confirmed any positive effect of diabetes empowerment on mastery appears to be eroded 
in the presence of diabetes distress and depression.
The literature evidences the importance of mastery in chronic conditions, positively 
impacting self-management and treatment adherence (Roepke & Grant, 2011). The 
results from the current analysis provide insight into the mechanisms by which mastery 
is impacted, with contributing factors possibly more salient for the cohort involved in 
this study. Evidence suggests that diabetes distress is chronic, in that if it remains 
unresolved it can become more pervasive as the condition progresses (Hessler et al., 
2020). Those with T2D transitioning to injection therapy are a unique population as they 
usually have been living and coping with the condition for a longer duration, therefore 
diabetes distress may be more prominent among this group. The current findings provide 
the basis for a more comprehensive understanding of the relationship between distress 
and mastery, recognising the impact of depression which presents as a common diabetes 
comorbidity (Lee, 2015; Nefs et al., 2013). Unpacking these associations may allow for 
development of better self-management promotion, strategies and interventions for this 
population. Indeed, calls for interventions to address diabetes distress to improve self- 
management and associated outcomes for those with diabetes may not offer effective 
solutions for this population if efforts are not made to tackle depression also.
There are some limitations with this study which should be recognised. This study 
utilises baseline data from an RCT, as such provides a snapshot of the population. A lack 
of longitudinal assessment limits our understanding of the changing nature of distress, 
depression, empowerment and mastery among this population as they navigate the 
challenges of injectables. Although a cross-sectional approach is suitable for this type 
of moderation study, a longitudinal study would have allowed for evidencing of injectable 
therapy adherence as a covariate in the model. Secondly, the study relies on self-report 
measures for data collection and therefore may be more influenced by participants’ 
subjective views.
Overall, this study identified the relationship between diabetes distress and mastery is 
moderated by depression, undermining the impact of diabetes empowerment. These 
findings have important implications for those involved in the care of those with T2D 
requiring injectables to achieve optimal glycaemic control. Within the diabetes specialist 
services, diabetes distress and empowerment may be modulated through specific educa-
tion to promote understanding about managing the injections and the implications of 
this additional treatment or through conversations to help resolve individual worries. 
However, these results indicate depression moderates the relationship between distress 
and mastery, accordingly it is not enough to simply target distress; if the individual also 
presents with depression then this must also be treated before mastery improves. As 
treating depression falls beyond the current remit of the diabetes clinicians and educa-
tors, a multi-disciplinary approach may be merited.
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